New hope for tough lung cancer cases: experimental drugs challenge standard treatment
NCT ID NCT07459751
Summary
This global study is testing whether new drug combinations work better than standard chemotherapy for advanced squamous lung cancer that has worsened after initial treatment. Researchers will compare two experimental approaches—one using a single new drug and another combining two new drugs—against the current standard treatment, docetaxel. The study aims to see if these new options help patients live longer or slow cancer growth with manageable side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED OR METASTATIC SQUAMOUS NON-SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Cancer Hospital, Chinese Academy of Medical Sciences
Beijing, Beijing Municipality, 100021, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.